Jazz Pharmaceuticals plc Business Combination, Acquisition Related Costs
Jazz Pharmaceuticals plc (JAZZ) reported Business Combination, Acquisition Related Costs of $700.00 thousand for the 3-month period ending 2016-12-31, per its 10-K filed 2018-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2018-02-27
- Jazz Pharmaceuticals plc business combination, acquisition related costs for the quarter ending 2016-12-31 was $700.00K.
- Jazz Pharmaceuticals plc business combination, acquisition related costs for the quarter ending 2016-09-30 was $10.80M.
- Jazz Pharmaceuticals plc business combination, acquisition related costs for the quarter ending 2016-06-30 was $2.20M.
- Jazz Pharmaceuticals plc business combination, acquisition related costs for the quarter ending 2014-12-31 was $5.20M, a 18.18% increase year-over-year.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2016-12-31 | $700.00K 10-K · filed 2018-02-27 | $11.50M derived: sum of 2 quarters · filed 2018-02-27 | $13.70M derived: sum of 3 quarters · filed 2018-02-27 | |
| 2016-09-30 | $10.80M 10-K · filed 2018-02-27 | $13.00M derived: sum of 2 quarters · filed 2018-02-27 | ||
| 2016-06-30 | $2.20M 10-K · filed 2018-02-27 | |||
| 2014-12-31 | $5.20M 10-K · filed 2016-02-23 | $5.90M derived: sum of 2 quarters · filed 2016-02-23 | $10.30M derived: sum of 3 quarters · filed 2016-02-23 | $27.40M derived: sum of 4 quarters · filed 2016-02-23 |
| 2014-09-30 | $700.00K 10-K · filed 2016-02-23 | $5.10M derived: sum of 2 quarters · filed 2016-02-23 | $22.20M derived: sum of 3 quarters · filed 2016-02-23 | $26.60M derived: sum of 4 quarters · filed 2016-02-23 |
| 2014-06-30 | $4.40M 10-K · filed 2016-02-23 | $21.50M derived: sum of 2 quarters · filed 2016-02-23 | $25.90M derived: sum of 3 quarters · filed 2016-02-23 | |
| 2014-03-31 | $17.10M 10-K · filed 2016-02-23 | $21.50M derived: sum of 2 quarters · filed 2016-02-23 | ||
| 2013-12-31 | $4.40M 10-K · filed 2015-02-24 | |||
| 2013-06-30 | $400.00K 10-K · filed 2015-02-24 | |||
| 2012-06-30 | $8.90M 10-K · filed 2014-02-25 | $12.40M derived: sum of 2 quarters · filed 2014-02-25 | $17.70M derived: sum of 3 quarters · filed 2014-02-25 | $23.70M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $3.50M 10-K · filed 2014-02-25 | $8.80M derived: sum of 2 quarters · filed 2014-02-25 | $14.80M derived: sum of 3 quarters · filed 2014-02-25 | |
| 2011-12-31 | $5.30M 10-K · filed 2013-02-26 | $11.30M derived: sum of 2 quarters · filed 2013-02-26 | ||
| 2011-09-30 | $6.00M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |